Results 141 to 150 of about 207,794 (393)

SPARCL1 and NT‐proBNP as biomarkers of right ventricular‐to‐pulmonary artery uncoupling in pulmonary hypertension

ESC Heart Failure, Volume 12, Issue 2, Page 1416-1426, April 2025.
Abstract Aims SPARCL1 was recently identified as a biomarker of right ventricular (RV) maladaptation in patients with pulmonary hypertension (PH), and N‐terminal pro‐brain natriuretic protein (NT‐proBNP) is an established biomarker of RV failure in PH. The present study investigated whether NT‐proBNP and SPARCL1 concentrations are associated with load ...
Oliver Dörr, Stanislav Keranov, Paulina van Wickern, Holger Nef, Christian Hamm, Pascal Bauer, Christian Troidl, Samuel Sossalla, Sandra Voss, Christoph Liebetrau, Manuel J. Richter, Henning Gall, Werner Seeger, Ardeschir Ghofrani, Athiththan Yogeswaran, Khodr Tello   +15 more
wiley   +1 more source

Predicting acute decompensated heart failure using circadian markers from heart rate time series

ESC Heart Failure, EarlyView.
Circadian metrics—amplitude, mesor, and acrophase—derived from a wrist‐worn heart rate monitor can predict acute decompensated heart failure (ADHF) up to 21 days before onset. In 65 post‐ADHF patients, an LSTM model achieved 74% sensitivity, and 73% specificity trained on 21‐day sequences. These findings support circadian rhythm analysis as a promising
Valerie A. A. van Es, Mayke M. C. J. van Leunen, Ignace L. J. de Lathauwer, Cindy C. A. G. Verstappen, René A. Tio, Ruud F. Spee, Lu Yuan, Monica Betta, Giacomo Handjaras, Hareld M. C. Kemps   +9 more
wiley   +1 more source

Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry [PDF]

, 2020
Jürgen Behr, Antje Prasse, Hubert Wirtz, Dirk Koschel, David Pittrow, Matthias Held, Jens Klotsche, Stefan Andreas, Martin Claussen, Christian Grohé, Heinrike Wilkens, Lars Hagmeyer, Dirk Skowasch, Joachim Meyer, J Kirschner, Sven Gläser, Nicolas Kahn, Tobias Welte, Claus Neurohr, Martin Schwaiblmair, Thomas Bahmer, Tim Oqueka, Marion Frankenberger, Michael Kreuter   +23 more
openalex   +1 more source

Four decades of heart–lung transplantation: Milestones and outcomes in advanced cardiorespiratory failure

ESC Heart Failure, EarlyView.
Abstract Aims Heart–lung transplantation (HLTx) remains a life‐saving intervention for patients with end‐stage cardiopulmonary failure. We retrospectively analysed long‐term HLTx outcomes at our centre to assess survival trends and evaluate the impact of evolving immunosuppressive, surgical and perioperative strategies.
L. Lily Rosenthal, Anna Maria Mühlbauer, Carola Grinninger, Nikolaus A. Haas, Heinrich Netz, Robert Dalla Pozza, Jürgen Hörer, Sebastian Michel, R. Schramm, D. Graetz, Christian Hagl   +10 more
wiley   +1 more source

Update on diagnosis and treatment of idiopathic pulmonary fibrosis

Jornal Brasileiro de Pneumologia, 2015
Idiopathic pulmonary fibrosis is a type of chronic fibrosing interstitial pneumonia, of unknown etiology, which is associated with a progressive decrease in pulmonary function and with high mortality rates. Interest in and knowledge of this disorder have
José Baddini-Martinez, Bruno Guedes Baldi, Cláudia Henrique da Costa, Sérgio Jezler, Mariana Silva Lima, Rogério Rufino   +5 more
doaj   +1 more source

Effect of Antifibrotic Therapy on Mortality and Survival Outcomes in Idiopathic Pulmonary Fibrosis [PDF]

, 2021
Samuel C. Schecter, Vikas Koppurapu, Y. Zemkova, D. Barber, Y S Shim, Archana Laroia, C.H. Lee, Kamonpun Ussavarungsi   +7 more
openalex   +1 more source

Circulating oxylipins predict mortality in heart failure with preserved ejection fraction

ESC Heart Failure, EarlyView.
A targeted LC–MS lipidomics approach identified arterial 15‐keto PGF2a as associated with 5‐year mortality in 90 patients with HFpEF. Abstract Aims Heart failure with preserved ejection fraction (HFpEF) poses significant diagnostic, prognostic and therapeutic challenges, with high morbidity and mortality rates.
Vaishnavi Aradhyula, Sareeta Manandhar, Alborz Sherafati, Alex Kloster, Anas Fares, Prabhatchandra Dube, Pamela S. Brewster, George V. Moukarbel, Krishna Rao Maddipati, Steven T. Haller, David J. Kennedy, Rajesh Gupta, Samer J. Khouri   +12 more
wiley   +1 more source

Rapidly Progressive Pulmonary Fibrosis in a Patient Treated with Danazol for Idiopathic Thrombocytopenic Purpura

Canadian Respiratory Journal, 2004
The case of a patient that developed pulmonary fibrosis two months after initiation of danazol for treatment of idiopathic thrombocytopenic purpura is described.
Smita Pakhale, Yuri Moltyaner, Dean Chamberlain, Neil Lazar   +3 more
doaj   +1 more source

Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets

International Journal of Molecular Sciences, 2019
Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial pulmonary disease with a median survival of 2–4 years after diagnosis.
Beatriz Ballester, J. Milara, J. Cortijo
semanticscholar   +1 more source

Role of NPPB for recovery post ventricular assist device in paediatric dilated cardiomyopathy: Single‐cell multiomics

ESC Heart Failure, EarlyView.
This study investigated factors associated with left ventricular recovery after LVAD implantation in paediatric dilated cardiomyopathy. Patients were classified into recovery and non‐recovery groups. Single‐nucleus sequencing revealed higher NPPB expression and altered apoptosis‐related pathways in the recovery group.
Yosuke Kugo, Takuji Kawamura, Akima Harada, Yuji Tominaga, Kenji Miki, Hidekazu Ishida, Takayoshi Ueno, Shigeru Miyagawa   +7 more
wiley   +1 more source